Twenty-eight patients with primary SS included in the multicenter , randomized , double-blind , placebo-controlled Tolerance and Efficacy of Rituximab in Primary Sjgren 's Syndrome ( TEARS ) trial underwent salivary gland ultrasonography before the first placebo or rituximab infusion and then 6 months later .